Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06320444 |
Recruitment Status :
Recruiting
First Posted : March 20, 2024
Last Update Posted : March 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Motor Neuron Disease, Amyotrophic Lateral Sclerosis Motor Neuron Disease Progressive Spinal Muscle Atrophy Primary Lateral Sclerosis Multiple Sclerosis Postpoliomyelitis Syndrome | Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG) |
Background:
Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due its unique alignment in the spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients.
Aim:
To develop, test, and employ non-invasive techniques to explore (dys)function between motor, sensory brain, and spinal networks in ALS. The project will address if the electrical activity of the cortical-spinal network by the of use peripheral stimulation (vibration, electrical nerve stimulation) to probe and reveal the normal or abnormal communication between brain and spinal networks. It is expected to reveal novel neurophysiological signatures in ALS patients compared to healthy controls.
Study Design & Data Analysis:
Surface electrodes will be mounted over the targeted regions in conjunction with High-Density EEG and High-density Electromyography (EMG). A physical and mathematical model of the underlying sources of electric activity (source localization) will be carried out at rest, during task, and with non-invasive peripheral nerve stimulation (PNS) and TMS. A separate paradigm will augment sensorimotor communication between the primary motor cortex (M1) and the somatosensory cortex (S1). Mild vibration (5N/< 500 grams) will be applied to the wrist and/or bicep tendon transcutaneously. Vibration in conjunction with non-invasive peripheral nerve stimulation will induce transient changes (30 seconds maximum) in the intrinsic excitability of motor neurons in the spinal cord. Surface EMG will capture altered MN activity at the spinal level and the anticipated augmented communication in cortical networks (S1-M1) will be captured with EEG through connectivity analysis. Non-invasive transcranial magnetic stimulation in conjunction with vibration/nerve stimulation will be recorded to explore upper motor neurone influences on the altered intrinsic excitability of spinal motor neurons.
Data collection:
EXG-EEG-EMG and TMS/Peripheral Stimulation recordings will be conducted using a BioSemi® ActiveTwo system with 128 active sintered Ag-AgCl electrodes and headcaps (BioSemi B.V., Amsterdam, The Netherlands). The TMS system is a Brainbox DuoMAG (Brainbox Ltd., Cardif, Wales, UK) which can be used with a Digitimer peripheral stimulator.
Study Type : | Observational |
Estimated Enrollment : | 240 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Developing Novel Non-invasive Electrophysiological Biomarkers of Dysfunction in Spinal and Cortical Pathways and Sensorimotor Impairments in Motor Neurone Disease |
Actual Study Start Date : | June 15, 2023 |
Estimated Primary Completion Date : | December 15, 2024 |
Estimated Study Completion Date : | July 15, 2025 |
Group/Cohort | Intervention/treatment |
---|---|
Controls
Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
|
Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory) Other Names:
|
Amyotrophic lateral sclerosis Patients |
Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory) Other Names:
|
Multiple Sclerosis patients |
Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory) Other Names:
|
Postpoliomyelitis syndrome patients |
Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory) Other Names:
|
Muscular Atrophy patients |
Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory) Other Names:
|
- Biomarker of sensorimotor integration [ Time Frame: Baseline to 2-years after baseline ]
A viable biomarker of sensorimotor integration for reliable and early distinction between healthy people and Motor Neuron Disease patient sub-phenotypes.
This will be achieved by comparing connectivity measures between EEG, Non-cortical CNS, and EMG electrophysiological signals. The integration will also be seen in spectral analysis measures.
- Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALS [ Time Frame: Baseline ]The sensorimotor integration and signature biomarkers achieved during outcome 1 will be correlated with the clinical scores and will be statistically tested for reliability and robustness. The effect sizes of these statistical and correlation matrices will be used to evaluate the feasibility of the signatures as reliable biomarkers for motor neuron conditions like ALS.
- Non-invasive recording of the SC functional neuro-electric activity [ Time Frame: Baseline ]Understanding the role of spinal cord (SC) in neuromuscular physiology (in both impaired and healthy individuals) and will also assist in discovering biomarkers in Brain-SC Peripheral connections. This is a perspective outcome that will be future based upon the inferences gained by the first two outcomes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
Healthy Volunteers:
- age and gender matched to patient groups
- intact physical ability to take part in the experiment.
Patients:
- Diagnosis of ALS, PLS, PMA, SMA, Polio or MS
- capable of providing informed consent.
Exclusion Criteria:
-
Healthy Controls:
- History of neuromuscular
- neurological or active psychiatric disease disease
- history of reaction or allergy to recording environments, equipment and the recording gels.
Patients:
- presence of active psychiatric disease
- any medical condition associated with severe neuropathy (e.g. poorly controlled diabetes).
- History of reaction or allergy to recording environments, equipment and the recording gels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06320444
Contact: Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN | +353 1 896 4497 | hardimao@tcd.ie | |
Contact: Prabhav Mehra, B.E. MSc. | +353 0894781347 | mehrap@tcd.ie |
Ireland | |
Academic Unit of Neurology, Trinity College Dublin, The University of Dublin | Recruiting |
Dublin, Leinster, Ireland, Dublin 2 | |
Contact: Orla Hardiman,, BSc MB BCh BAO MD FRCPI FAAN +353 1 896 4497 hardimao@tcd.ie | |
Contact: Prabhav Mehra, BE MSc +3530894781347 mehrap@tcd.ie |
Principal Investigator: | Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN | Academic Unit of Neurology, Trinity College Dublin, The University of Dublin |
Responsible Party: | Orla Hardiman, Professor of Neurology, University of Dublin, Trinity College |
ClinicalTrials.gov Identifier: | NCT06320444 |
Other Study ID Numbers: |
CRFSJ0297 |
First Posted: | March 20, 2024 Key Record Dates |
Last Update Posted: | March 20, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Raw data from this study may be made available in anonymized form upon request from qualified investigators subject to the approval by the Data Protection Office (DPO) and Office of Corporate Partnership and Knowledge Exchanges (OCPKE) in Trinity College Dublin, the University of Dublin. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
Time Frame: | Due to ethical constraints and the time required for data quality checks, data will only be made available in fully anonymised format following the publication of results. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Electroencephalography (EEG) Peripheral Nerve Stimulation Vibration-Induced Stimulation Neurodegeneration |
Electrophysiology Biomarkers Neuromuscular Physiology Spinal Connectivity |
Postpoliomyelitis Syndrome Multiple Sclerosis Motor Neuron Disease Amyotrophic Lateral Sclerosis Muscular Atrophy Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Atrophy Pathological Conditions, Anatomical |
Neurodegenerative Diseases Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Neuromuscular Manifestations Neurologic Manifestations Poliomyelitis Myelitis Central Nervous System Infections Infections Enterovirus Infections Picornaviridae Infections |